Showing results (151-160 of 192) with videos related to
Sort By:
Pageof 20
Cancer Research|September 17, 2017
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer ProgressionYi Liang, Musaddeque Ahmed, Haiyang Guo, et al.European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumorsFlorentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.Cancer Research Communications|March 6, 2023
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian CancerStefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Neoadjuvant Enzalutamide Prior to ProstatectomyBruce Montgomery, Maria S Tretiakova, Anthony M Joshua, et al.European Urology Focus|April 12, 2025
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated VariantsMitchell G Lawrence, Shivakumar Keerthikumar, Scott L Townley, et al.Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.The New England Journal of Medicine|June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid, Caroline Robert, Adil Daud, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.Pageof 20